TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
Healthcare
$0.82 +2.23%
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
52W Low $0.85High $2.57
Volume 0.00M
Average 0.81M
Income Statement
Follow revenue through to earnings.
Revenue
$10.32M
FY 2025 · Annual
+266.7% YoYOperating Income
-$135.81M
FY 2025 · Annual
Net Income
-$129.77M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.14M | 13.54M | 21.05M | 2.82M | 10.33M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.87M |
| Gross Profit | 10.14M | 13.54M | 21.05M | 2.82M | 7.46M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 72.2% |
| Research & Development | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
| Selling, General & Admin | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M |
| Operating Expenses | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| EBITDA | (45.3M) | (59.91M) | (80.1M) | (119.74M) | (124.13M) |
| EBITDA Margin | -446.7% | -442.6% | -380.5% | -4252.1% | -1202.2% |
| Operating Income | (48.64M) | (66.64M) | (93.46M) | (134.82M) | (135.81M) |
| Operating Margin | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Interest Income | 16K | 1.59M | 8M | 12.07M | 8.82M |
| Interest Expense | 0 | 1.18M | 3.76M | 3.65M | 2.77M |
| Other Income / Expenses | 16K | 415K | 4.24M | 7.32M | 6.05M |
| Income Before Tax | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Pre-Tax Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Net Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| EPS (Basic) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| EPS (Diluted) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| 23.91M | 24.05M | 65.6M | 111.99M | 129.86M | |
| 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
TCRX Earnings Waterfall · TTM
NASDAQ:TCRX · Revenue to Net Income
Key Ratios
EPS$-0.96
Gross Margin82.4%
Net Margin-1609.4%
P/E Ratio-1.4
P/S Ratio84.9
Analysis
$9.1M of revenue converted into -$124.3M of net income for the selected period. Gross margin is 82.4% and net margin is -1609.4%, showing how much revenue survives after costs and taxes. EPS is $-0.96, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jun 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 22, 2026 | |
| 8-K | Current report | May 22, 2026 |
How much revenue does TCRX generate?
TScan Therapeutics, Inc. (TCRX) reported $10.32M of revenue in fiscal 2025.
Is TCRX profitable?
TScan Therapeutics, Inc. (TCRX) reported -$129.77M of net income, with a net margin of -1256.8%.
Continue the stock analysis
Jump to another research area for this company.